What works? Every peptide, ranked by human evidence

For each goal, this ranks every peptide in the encyclopedia by how much and how strong its evidence in people is — the PubMed trials counted, the FDA status, and a link to the sourced dose on each entry. It is a map of where the evidence actually is, not advice and not a verdict: a high score means a peptide is well studied and, often, approved for something — not that it is right, safe or legal for what you have in mind. Volume (how much research) and grade (how strong) sit side by side so neither misleads, and every rank can be re-derived from the columns shown. Grey Peptides sells nothing and links to no vendor.

Weight loss and metabolism

1. Regular human insulin high · score 100
2. Insulin degludec / liraglutide (IDegLira) high · score 100
3. Insulin glargine / lixisenatide (iGlarLixi) high · score 100
4. Liraglutide high · score 100
5. Semaglutide high · score 100
6. Insulin glargine high · score 100

Healing, injury and recovery

1. Abaloparatide high · score 100
2. Difelikefalin high · score 100
3. Palopegteriparatide high · score 100
4. Calcitonin high · score 90
5. Teriparatide high · score 90
6. Linaclotide high · score 90

Skin and hair

1. Hyaluronic Acid high · score 90
2. Botulinum Toxin high · score 90
3. Pal-GHK medium · score 65
4. Argireline medium · score 65
5. Collagen Peptides medium · score 55
6. Palmitoyl Pentapeptide-4 medium · score 55

Focus, mood and the brain

1. Trofinetide high · score 100
2. Cerebrolysin high · score 90
3. Ziconotide high · score 90
4. Nerinetide medium · score 70
5. Sovateltide medium · score 70
6. Pegsebrenatide medium · score 70

Growth hormone and body composition

1. Thyrotropin alfa high · score 100
2. Tesamorelin high · score 100
3. Vosoritide high · score 100
4. Somapacitan high · score 100
5. Somatrogon high · score 100
6. Lonapegsomatropin high · score 100

Heart and circulation

1. Bivalirudin high · score 100
2. Eptifibatide high · score 100
3. Sotatercept high · score 100
4. Angiotensin II high · score 90
5. Erythropoietin (EPO) high · score 90
6. Vasopressin high · score 90

Sexual and reproductive health

1. Afamelanotide high · score 100
2. Urofollitropin high · score 100
3. Relugolix high · score 100
4. Follitropin beta high · score 100
5. Elagolix high · score 100
6. PT-141 high · score 100

Longevity and cell health

1. Elamipretide high · score 100
2. SS-31 (Elamipretide) high · score 100
3. GDF15 high · score 80
4. Melatonin medium · score 65
5. Klotho Peptide medium · score 55
6. Carnosine medium · score 55

Immune defence and infection

1. Cyclosporine high · score 100
2. Colistin high · score 100
3. Polymyxin B high · score 100
4. Glatiramer Acetate high · score 100
5. Caspofungin high · score 100
6. Bacitracin high · score 100

Diagnostic and research tools

1. Bleomycin high · score 100
2. Dactinomycin high · score 100
3. Lutetium-177 DOTATATE high · score 100
4. Gozetotide high · score 100
5. Carfilzomib high · score 100
6. Vipivotide Tetraxetan high · score 100

In development

1. Apitegromab high · score 100
2. Insulin efsitora alfa high · score 90
3. Efpeglenatide high · score 90
4. Apraglutide high · score 90
5. Taspoglutide high · score 85
6. CagriSema high · score 80

GoalAll goalsWeight loss and metabolismHealing, injury and recoverySkin and hairFocus, mood and the brainGrowth hormone and body compositionHeart and circulationSexual and reproductive healthLongevity and cell healthImmune defence and infectionDiagnostic and research toolsIn development

Evidence gradeAny gradeHighMediumLowUngraded

Regulatory statusAny statusFDA approvedIn trialsDiagnosticDiscontinuedFood additiveIn developmentApproved abroadPreclinicalResearch onlySupplementVeterinaryWithdrawn

Search name

Has a human trial on this page

660 peptides · sorted by evidence score (click a column to re-sort)

Peptide	Goal	Grade	Human studies	RCTs	Max trial phase	Regulatory	Dose	Score
Regular human insulin	Weight loss and metabolism	High	322,825	23,135	Phase 4	FDA approved	—	100
Cyclosporine	Immune defence and infection	High	34,891	2,298	Phase 4	FDA approved	—	100
Bleomycin	Diagnostic and research tools	High	11,840	593	Phase 4	FDA approved	intravenous, intramuscular or subcutaneous →	100
Colistin	Immune defence and infection	High	7,551	193	Phase 4	FDA approved	intravenous or intramuscular →	100
Dactinomycin	Diagnostic and research tools	High	6,715	144	Phase 4	FDA approved	intravenous →	100
Insulin degludec / liraglutide (IDegLira)	Weight loss and metabolism	High	4,323	758	Phase 4	FDA approved	—	100
Polymyxin B	Immune defence and infection	High	3,679	167	Phase 4	FDA approved	intravenous →	100
Insulin glargine / lixisenatide (iGlarLixi)	Weight loss and metabolism	High	3,511	959	Phase 4	FDA approved	—	100
Liraglutide	Weight loss and metabolism	High	3,480	566	Phase 4	FDA approved	subcutaneous →	100
Semaglutide	Weight loss and metabolism	High	3,327	313	Phase 4	FDA approved	subcutaneous (Ozempic/Wegovy); oral daily (Rybelsus) →	100
Glatiramer Acetate	Immune defence and infection	High	3,181	129	Phase 4	FDA approved	subcutaneous →	100
Insulin glargine	Weight loss and metabolism	High	3,173	914	Phase 4	FDA approved	—	100
Lutetium-177 DOTATATE	Diagnostic and research tools	High	2,857	56	Phase 4	FDA approved	intravenous infusion →	100
Caspofungin	Immune defence and infection	High	2,535	55	Phase 4	FDA approved	sourced dose →	100
Bacitracin	Immune defence and infection	High	1,884	139	Phase 4	FDA approved	—	100
Bivalirudin	Heart and circulation	High	1,765	288	Phase 4	FDA approved	intravenous →	100
NPH insulin (isophane)	Weight loss and metabolism	High	1,738	451	Phase 4	FDA approved	—	100
Gozetotide	Diagnostic and research tools	High	1,665	33	Phase 3	FDA approved	intravenous →	100
Micafungin	Immune defence and infection	High	1,499	43	Phase 4	FDA approved	—	100
Tirzepatide	Weight loss and metabolism	High	1,475	136	Phase 4	FDA approved	subcutaneous →	100
Insulin lispro	Weight loss and metabolism	High	1,396	422	Phase 4	FDA approved	—	100
Carfilzomib	Diagnostic and research tools	High	1,392	72	Phase 4	FDA approved	intravenous →	100
Eptifibatide	Heart and circulation	High	1,189	189	Phase 4	FDA approved	intravenous →	100
Vipivotide Tetraxetan	Diagnostic and research tools	High	1,001	33	Phase 4	FDA approved	intravenous →	100
Technetium Tc 99m mertiatide	Diagnostic and research tools	High	967	4	—	FDA approved	intravenous →	100
Anidulafungin	Immune defence and infection	High	915	13	Phase 4	FDA approved	—	100
Thyrotropin alfa	Growth hormone and body composition	High	800	48	Phase 4	FDA approved	intramuscular →	100
Romidepsin	Diagnostic and research tools	High	784	7	Phase 3	FDA approved	intravenous →	100
Indium In 111 pentetreotide	Diagnostic and research tools	High	693	3	Phase 4	FDA approved	—	100
Gramicidin	Immune defence and infection	High	681	32	Phase 3	FDA approved	topical or ophthalmic only →	100
Dalbavancin	Immune defence and infection	High	566	15	Phase 4	FDA approved	sourced dose →	100
Lixisenatide	Weight loss and metabolism	High	522	95	Phase 4	FDA approved	—	100
Afamelanotide	Sexual and reproductive health	High	437	8	Phase 3	FDA approved	subcutaneous implant →	100
Oritavancin	Immune defence and infection	High	336	9	Phase 4	FDA approved	sourced dose →	100
Telavancin	Immune defence and infection	High	328	18	Phase 4	FDA approved	—	100
Piflufolastat F 18	Diagnostic and research tools	High	322	4	Phase 4	FDA approved	intravenous →	100
Insulin glulisine	Weight loss and metabolism	High	315	85	Phase 4	FDA approved	—	100
Abaloparatide	Healing, injury and recovery	High	277	32	Phase 4	FDA approved	subcutaneous →	100
Bulevirtide	Immune defence and infection	High	250	11	Phase 3	FDA approved	subcutaneous →	100
Urofollitropin	Sexual and reproductive health	High	239	59	Phase 4	FDA approved	—	100
Metreleptin	Weight loss and metabolism	High	238	29	Phase 4	FDA approved	subcutaneous →	100
Rezafungin	Immune defence and infection	High	216	14	Phase 4	FDA approved	intravenous infusion →	100
Elamipretide	Longevity and cell health	High	202	19	Phase 4	FDA approved	subcutaneous →	100
Relugolix	Sexual and reproductive health	High	191	32	Phase 4	FDA approved	oral →	100
Sotatercept	Heart and circulation	High	189	13	Phase 4	FDA approved	subcutaneous →	100
Follitropin beta	Sexual and reproductive health	High	180	59	Phase 4	FDA approved	subcutaneous →	100
Ecallantide	Immune defence and infection	High	158	11	Phase 3	FDA approved	—	100
Voclosporin	Immune defence and infection	High	157	16	Phase 4	FDA approved	oral →	100
Elagolix	Sexual and reproductive health	High	145	26	Phase 4	FDA approved	oral →	100
Etelcalcetide	Weight loss and metabolism	High	114	17	Phase 4	FDA approved	intravenous →	100
Insulin icodec	Weight loss and metabolism	High	113	33	Phase 4	FDA approved	—	100
SS-31 (Elamipretide)	Longevity and cell health	High	108	16	Phase 2	FDA approved	subcutaneous →	100
Tesamorelin	Growth hormone and body composition	High	107	26	Phase 4	FDA approved	—	100
PT-141	Sexual and reproductive health	High	92	14	Phase 3	FDA approved	subcutaneous →	100
Vosoritide	Growth hormone and body composition	High	89	7	Phase 3	FDA approved	subcutaneous →	100
Difelikefalin	Healing, injury and recovery	High	78	13	Phase 3	FDA approved	intravenous →	100
Somapacitan	Growth hormone and body composition	High	65	23	Phase 3	FDA approved	subcutaneous →	100
Zilucoplan	Immune defence and infection	High	57	6	Phase 3	FDA approved	subcutaneous (self-injection) →	100
Somatrogon	Growth hormone and body composition	High	54	12	Phase 3	FDA approved	subcutaneous →	100
Trofinetide	Focus, mood and the brain	High	54	9	Phase 3	FDA approved	oral →	100
Motixafortide	Immune defence and infection	High	48	5	Phase 4	FDA approved	subcutaneous →	100
Lonapegsomatropin	Growth hormone and body composition	High	35	6	Phase 3	FDA approved	subcutaneous →	100
Palopegteriparatide	Healing, injury and recovery	High	34	10	Phase 3	FDA approved	subcutaneous →	100
Macimorelin	Growth hormone and body composition	High	32	7	Phase 3	FDA approved	oral →	100
Apitegromab	In development	High	12	4	Phase 3	FDA approved	intravenous infusion →	100
Navepegritide	Growth hormone and body composition	High	9	4	Phase 3	FDA approved	—	100
Menotropin	Sexual and reproductive health	High	54,103	3,697	Phase 4	FDA approved	—	90
Angiotensin II	Heart and circulation	High	41,080	3,675	Phase 4	FDA approved	intravenous (central line preferred) →	90
Glucagon	Weight loss and metabolism	High	37,659	3,587	Phase 4	FDA approved	subcutaneous, intramuscular, or intranasal →	90
IGF-1	Growth hormone and body composition	High	37,304	2,408	Phase 4	FDA approved	subcutaneous →	90
Corticotropin	Growth hormone and body composition	High	35,809	1,271	Phase 4	FDA approved	intramuscular or subcutaneous →	90
HCG	Growth hormone and body composition	High	35,572	1,422	Phase 4	FDA approved	sourced dose →	90
Hyaluronic Acid	Skin and hair	High	34,639	1,932	Phase 4	FDA approved	—	90
Vancomycin	Immune defence and infection	High	28,069	757	Phase 4	FDA approved	intravenous or oral →	90
Mecasermin	Growth hormone and body composition	High	26,676	1,849	Phase 3	FDA approved	subcutaneous →	90
Erythropoietin (EPO)	Heart and circulation	High	26,425	1,746	Phase 4	FDA approved	—	90
Somatostatin	Growth hormone and body composition	High	24,896	1,176	Phase 4	Approved abroad	—	90
Calcitonin	Healing, injury and recovery	High	24,870	1,028	Phase 4	FDA approved	intranasal or subcutaneous →	90
Vasopressin	Heart and circulation	High	23,749	1,349	Phase 4	FDA approved	intravenous →	90
Botulinum Toxin	Skin and hair	High	22,038	1,690	Phase 4	FDA approved	—	90
Oxytocin	Sexual and reproductive health	High	17,006	2,151	Phase 4	FDA approved	—	90
ANP	Heart and circulation	High	16,152	1,226	Phase 4	Approved abroad	—	90
Octreotide	Growth hormone and body composition	High	10,156	541	Phase 4	FDA approved	subcutaneous or intravenous →	90
Alprostadil	Sexual and reproductive health	High	9,253	797	Phase 4	FDA approved	intracavernosal injection →	90
Corticorelin	Growth hormone and body composition	High	8,178	298	Phase 4	FDA approved	intravenous bolus →	90
Somatropin (HGH)	Growth hormone and body composition	High	7,503	590	Phase 4	FDA approved	—	90
Desmopressin	Heart and circulation	High	5,337	319	Phase 4	FDA approved	—	90
Secretin	Weight loss and metabolism	High	4,807	104	Phase 4	FDA approved	sourced dose →	90
Leuprolide	Sexual and reproductive health	High	3,328	563	Phase 4	FDA approved	—	90
Exenatide	Weight loss and metabolism	High	2,991	398	Phase 4	FDA approved	—	90
Daptomycin	Immune defence and infection	High	2,847	49	Phase 4	FDA approved	intravenous →	90
Tetracosactide	Growth hormone and body composition	High	2,086	162	Phase 4	FDA approved	intravenous or intramuscular →	90
Goserelin	Sexual and reproductive health	High	1,887	437	Phase 4	FDA approved	subcutaneous implant (anterior abdominal wall, below the navel) →	90
Triptorelin	Sexual and reproductive health	High	1,810	343	Phase 4	FDA approved	intramuscular →	90
Buserelin	Sexual and reproductive health	High	1,781	271	Phase 4	Approved abroad	—	90
Teriparatide	Healing, injury and recovery	High	1,424	108	Phase 4	FDA approved	subcutaneous →	90
Insulin aspart	Weight loss and metabolism	High	1,385	469	Phase 4	FDA approved	—	90
Follitropin alfa	Sexual and reproductive health	High	1,321	83	Phase 4	FDA approved	—	90
Lanreotide	Growth hormone and body composition	High	1,202	92	Phase 4	FDA approved	—	90
Terlipressin	Heart and circulation	High	1,092	147	Phase 4	FDA approved	intravenous →	90
Dulaglutide	Weight loss and metabolism	High	874	153	Phase 4	FDA approved	subcutaneous →	90
Romiplostim	Immune defence and infection	High	792	39	Phase 4	FDA approved	subcutaneous →	90
Insulin degludec	Weight loss and metabolism	High	784	224	Phase 4	FDA approved	—	90
Icatibant	Heart and circulation	High	742	34	Phase 4	FDA approved	subcutaneous →	90
Edotreotide	Diagnostic and research tools	High	736	4	Phase 3	FDA approved	intravenous →	90
Pasireotide	Growth hormone and body composition	High	679	55	Phase 4	FDA approved	subcutaneous →	90
Pegvisomant	Growth hormone and body composition	High	624	39	Phase 4	FDA approved	subcutaneous →	90
Thymosin α1	Immune defence and infection	High	556	64	Phase 3	Approved abroad	subcutaneous →	90
Cetrorelix	Sexual and reproductive health	High	553	112	Phase 4	FDA approved	subcutaneous →	90
Gallium Ga 68 dotatate	Diagnostic and research tools	High	482	2	Phase 4	FDA approved	—	90
Linaclotide	Healing, injury and recovery	High	419	47	Phase 4	FDA approved	oral →	90
Cerebrolysin	Focus, mood and the brain	High	348	62	Phase 4	Approved abroad	—	90
Nafarelin	Sexual and reproductive health	High	318	67	Phase 4	FDA approved	—	90
Degarelix	Sexual and reproductive health	High	304	52	Phase 4	FDA approved	subcutaneous (abdomen) →	90
Ganirelix	Sexual and reproductive health	High	282	77	Phase 4	FDA approved	subcutaneous (thigh or abdomen) →	90
Teduglutide	Weight loss and metabolism	High	279	23	Phase 4	FDA approved	subcutaneous →	90
Ziconotide	Focus, mood and the brain	High	276	4	Phase 4	FDA approved	—	90
Pegcetacoplan	Immune defence and infection	High	242	34	Phase 4	FDA approved	subcutaneous infusion; intravitreal →	90
Setmelanotide	Weight loss and metabolism	High	158	6	Phase 4	FDA approved	subcutaneous →	90
Polaprezinc	Healing, injury and recovery	High	141	31	Phase 4	Approved abroad	oral →	90
Vapreotide	Weight loss and metabolism	High	137	4	Phase 3	In trials	—	90
Histrelin	Sexual and reproductive health	High	135	2	Phase 3	FDA approved	subcutaneous implant (inner aspect of upper arm) →	90
Trafermin	Healing, injury and recovery	High	110	12	Phase 3	Approved abroad	topical spray →	90
Plecanatide	Healing, injury and recovery	High	97	11	Phase 3	FDA approved	oral →	90
Insulin efsitora alfa	In development	High	94	29	Phase 3	FDA approved	—	90
Mifamurtide	Immune defence and infection	High	92	6	Phase 2	Approved abroad	—	90
Follitropin delta	Sexual and reproductive health	High	67	21	Phase 4	Approved abroad	—	90
Thrombomodulin Alfa	Heart and circulation	High	59	9	Phase 3	Approved abroad	intravenous →	90
Tertomotide	Diagnostic and research tools	High	58	5	Phase 3	Approved abroad	injection (route not stated in the trial abstract) →	90
Melphalan Flufenamide	Diagnostic and research tools	High	56	3	Phase 3	Approved abroad	intravenous →	90
Mazdutide	Weight loss and metabolism	High	40	11	Phase 4	Approved abroad	—	90
Efpeglenatide	In development	High	38	12	Phase 3	In trials	subcutaneous →	90
Enlicitide	Heart and circulation	High	34	5	Phase 3	FDA approved	oral →	90
Copper Cu 64 dotatate	Diagnostic and research tools	High	30	0	Phase 4	FDA approved	—	90
Albuvirtide	Immune defence and infection	High	29	5	Phase 4	Approved abroad	—	90
Apraglutide	In development	High	25	2	Phase 3	In development	subcutaneous →	90
Polyethylene glycol loxenatide	Weight loss and metabolism	High	25	9	Phase 4	Approved abroad	subcutaneous →	90
Forigerimod	Immune defence and infection	High	22	2	Phase 3	Approved abroad	subcutaneous →	90
Icotrokinra	Immune defence and infection	High	21	9	Phase 3	FDA approved	oral →	90
Rusfertide	Weight loss and metabolism	High	17	5	Phase 3	FDA approved	subcutaneous →	90
Efsubaglutide alfa	Weight loss and metabolism	High	14	10	Phase 4	Approved abroad	subcutaneous →	90
Nelipepimut-S	Diagnostic and research tools	High	11	5	Phase 3	In trials	intradermal →	90
Flotufolastat F 18	Diagnostic and research tools	High	10	0	Phase 2	FDA approved	intravenous →	90
Cholecystokinin	Weight loss and metabolism	High	26,761	627	Phase 4	Diagnostic	IV (sincalide only) →	85
Aprotinin	Heart and circulation	High	3,445	416	Phase 4	Discontinued	intravenous →	85
Enfuvirtide	Immune defence and infection	High	969	65	Phase 4	Discontinued	subcutaneous →	85
Insulin detemir	Weight loss and metabolism	High	913	170	Phase 4	Discontinued	—	85
Parathyroid hormone (1-84)	Healing, injury and recovery	High	725	80	Phase 4	Discontinued	subcutaneous →	85
Lepirudin	Heart and circulation	High	475	11	Phase 4	Discontinued	intravenous →	85
Pramlintide	Weight loss and metabolism	High	404	67	Phase 4	Discontinued	subcutaneous →	85
Serelaxin	Heart and circulation	High	170	35	Phase 3	Discontinued	intravenous →	85
Desirudin	Heart and circulation	High	66	10	Phase 4	Discontinued	subcutaneous →	85
Taspoglutide	In development	High	55	11	Phase 3	Discontinued	subcutaneous →	85
Peginesatide	Heart and circulation	High	52	2	Phase 4	Discontinued	intravenous or subcutaneous →	85
Abarelix	Sexual and reproductive health	High	51	2	Phase 4	Withdrawn	intramuscular →	85
Insulin peglispro	Weight loss and metabolism	High	49	27	Phase 3	Discontinued	subcutaneous →	85
Lucinactant	Diagnostic and research tools	High	45	6	Phase 3	Discontinued	intratracheal →	85
Iseganan	Immune defence and infection	High	41	6	Phase 3	Discontinued	oral rinse (investigational) →	85
Dasiglucagon	Weight loss and metabolism	High	36	13	Phase 3	Discontinued	subcutaneous →	85
Surotomycin	Immune defence and infection	High	36	5	Phase 3	Discontinued	oral →	85
Capromorelin	Growth hormone and body composition	High	22	4	—	Veterinary	—	85
GDF15	Longevity and cell health	High	4,421	183	Phase 4	In trials	—	80
Teicoplanin	Immune defence and infection	High	2,847	122	Phase 4	Approved abroad	—	80
Atosiban	Sexual and reproductive health	High	383	55	Phase 4	Approved abroad	intravenous →	80
Carbetocin	Sexual and reproductive health	High	275	67	Phase 4	Approved abroad	IV or IM →	80
Anamorelin	Growth hormone and body composition	High	135	12	Phase 3	Approved abroad	oral →	80
Corifollitropin alfa	Sexual and reproductive health	High	122	33	Phase 4	Approved abroad	subcutaneous →	80
Survodutide	Weight loss and metabolism	High	58	10	Phase 3	In trials	subcutaneous →	80
CagriSema	In development	High	40	10	Phase 3	In development	subcutaneous →	80
Ecnoglutide	Weight loss and metabolism	High	12	5	Phase 3	Approved abroad	subcutaneous →	80
BNP	Heart and circulation	High	28,708	2,612	Phase 4	Diagnostic	—	75
Nesiritide	Heart and circulation	High	21,585	1,942	Phase 4	Discontinued	intravenous →	75
Protirelin	Growth hormone and body composition	High	9,961	267	Phase 3	Discontinued	—	75
Nisin	Immune defence and infection	High	473	6	Phase 2	Food additive	—	75
Albiglutide	Weight loss and metabolism	High	243	40	Phase 4	Discontinued	subcutaneous →	75
Ularitide	Heart and circulation	High	204	34	Phase 3	Discontinued	intravenous →	75
Pexiganan	Healing, injury and recovery	High	60	1	Phase 3	Discontinued	topical →	75
Omiganan	Healing, injury and recovery	High	35	5	Phase 3	Discontinued	—	75
VIP	Immune defence and infection	Medium	5,488	97	Phase 4	In trials	intravenous →	70
Nerinetide	Focus, mood and the brain	Medium	1,354	45	Phase 3	In trials	—	70
Kisspeptin-10	Sexual and reproductive health	Medium	748	17	Phase 3	In trials	—	70
Recombinant Human Endostatin	Diagnostic and research tools	Medium	390	43	Phase 4	Approved abroad	intravenous →	70
DOTANOC	Diagnostic and research tools	Medium	362	2	Phase 4	In trials	intravenous →	70
PSMA-1007	Diagnostic and research tools	Medium	317	6	Phase 3	Approved abroad	intravenous →	70
Cilengitide	Diagnostic and research tools	Medium	287	17	Phase 3	In trials	—	70
Pentixafor	Diagnostic and research tools	Medium	259	1	Phase 3	In trials	intravenous →	70
Avexitide	Weight loss and metabolism	Medium	223	35	Phase 4	In trials	subcutaneous →	70
Zadavotide Guraxetan	Diagnostic and research tools	Medium	172	3	Phase 3	In trials	intravenous →	70
Ornipressin	Heart and circulation	Medium	157	12	—	Approved abroad	intravenous →	70
RM2	Diagnostic and research tools	Medium	155	6	Phase 3	In trials	intravenous →	70
Tyrothricin	Immune defence and infection	Medium	153	7	Phase 4	Approved abroad	—	70
Thymostimulin	Immune defence and infection	Medium	151	37	Phase 3	Approved abroad	subcutaneous →	70
Retatrutide	Weight loss and metabolism	Medium	136	10	Phase 3	In trials	—	70
Plitidepsin	Diagnostic and research tools	Medium	121	6	Phase 3	Approved abroad	intravenous →	70
Nangibotide	Immune defence and infection	Medium	110	6	Phase 2	In trials	intravenous →	70
Orforglipron	Weight loss and metabolism	Medium	91	19	Phase 4	FDA approved	oral →	70
Bimagrumab	In development	Medium	88	15	Phase 3	In trials	—	70
Elcatonin	Healing, injury and recovery	Medium	82	15	—	Approved abroad	intramuscular →	70
Lancovutide	Diagnostic and research tools	Medium	60	3	Phase 2	Approved abroad	inhaled →	70
Sovateltide	Focus, mood and the brain	Medium	52	2	Phase 4	Approved abroad	—	70
Tecemotide	Diagnostic and research tools	Medium	41	9	Phase 3	In trials	—	70
Thymomodulin	Immune defence and infection	Medium	37	7	—	Approved abroad	oral →	70
Romurtide	Immune defence and infection	Medium	34	6	—	Approved abroad	subcutaneous →	70
DAPTA	Immune defence and infection	Medium	30	2	Phase 2	Approved abroad	intranasal →	70
Brimapitide	Diagnostic and research tools	Medium	27	4	Phase 3	Approved abroad	intratympanic →	70
Efruxifermin	In development	Medium	27	6	Phase 3	In trials	subcutaneous →	70
Fexapotide	Diagnostic and research tools	Medium	26	2	Phase 3	In trials	—	70
Pegozafermin	In development	Medium	25	6	Phase 3	In trials	subcutaneous →	70
Murepavadin	Immune defence and infection	Medium	24	1	Phase 3	In trials	intravenous →	70
Lusupultide	Diagnostic and research tools	Medium	23	5	—	Approved abroad	intratracheal →	70
Ulimorelin	Weight loss and metabolism	Medium	23	9	Phase 3	In trials	—	70
Solnatide	In development	Medium	21	6	Phase 2	In trials	inhaled →	70
Disomotide	Diagnostic and research tools	Medium	19	1	—	Approved abroad	subcutaneous →	70
Alfatide II	Diagnostic and research tools	Medium	15	1	Phase 4	In trials	intravenous →	70
Garetosmab	In development	Medium	15	6	Phase 3	FDA approved	—	70
Maraciclatide	Diagnostic and research tools	Medium	14	3	Phase 2	In trials	intravenous →	70
Dalazatide	Immune defence and infection	Medium	13	1	Phase 1	Approved abroad	subcutaneous →	70
Pegsebrenatide	Focus, mood and the brain	Medium	12	1	—	In trials	injection →	70
Teverelix	Sexual and reproductive health	Medium	12	2	Phase 2	In trials	subcutaneous and intramuscular →	70
Danegaptide	Heart and circulation	Medium	11	1	Phase 2	In trials	—	70
Satoreotide Trizoxetan	Diagnostic and research tools	Medium	11	1	Phase 2	In trials	intravenous →	70
Amilomotide	Focus, mood and the brain	Medium	10	2	—	Approved abroad	intramuscular →	70
Trofolastat	Diagnostic and research tools	Medium	10	1	—	In trials	intravenous →	70
Dazdotuftide	Immune defence and infection	Medium	9	1	—	In trials	topical eye drops →	70
Dirucotide	Immune defence and infection	Medium	9	2	Phase 3	In trials	—	70
Efinopegdutide	Weight loss and metabolism	Medium	9	3	Phase 2	In trials	—	70
DOTA-LM3	Diagnostic and research tools	Medium	8	3	Phase 2	In trials	intravenous →	70
Elpamotide	Diagnostic and research tools	Medium	8	1	—	Approved abroad	subcutaneous →	70
Bofanglutide	In development	Medium	7	6	Phase 3	In trials	subcutaneous →	70
Eloralintide	Weight loss and metabolism	Medium	7	3	Phase 3	In trials	subcutaneous →	70
Dusquetide	Immune defence and infection	Medium	4	2	Phase 3	In trials	—	70
Galinpepimut-S	Diagnostic and research tools	Medium	4	1	Phase 3	In trials	—	70
Rovatirelin	Focus, mood and the brain	Medium	4	1	—	In trials	—	70
Canvuparatide	In development	Medium	3	2	Phase 3	In trials	subcutaneous →	70
ECC5004	In development	Medium	2	2	Phase 3	In trials	oral →	70
VK2735	In development	Medium	1	1	Phase 3	In trials	subcutaneous →	70
Endothelin-1	Heart and circulation	Medium	18,754	1,181	Phase 4	Research only	—	65
Melatonin	Longevity and cell health	Medium	16,290	1,205	Phase 4	Supplement	—	65
C-peptide	Weight loss and metabolism	Medium	13,181	1,783	Phase 4	Research only	subcutaneous →	65
Bradykinin	Heart and circulation	Medium	8,791	309	Phase 4	Research only	—	65
Hepcidin	Weight loss and metabolism	Medium	4,148	237	Phase 4	Research only	—	65
Growth hormone-releasing hormone	Growth hormone and body composition	Medium	3,412	285	Phase 4	Research only	intravenous →	65
Parathyroid hormone-related protein	Healing, injury and recovery	Medium	2,911	10	Phase 4	Research only	subcutaneous →	65
Peptide YY	Weight loss and metabolism	Medium	2,896	557	Phase 4	Research only	—	65
Pancreatic polypeptide	Weight loss and metabolism	Medium	2,294	181	Phase 4	Research only	intravenous →	65
Neurotensin	Focus, mood and the brain	Medium	2,211	48	Phase 4	Research only	—	65
Bombesin	Weight loss and metabolism	Medium	1,827	14	Phase 3	Research only	—	65
Gastrin-releasing peptide	Weight loss and metabolism	Medium	1,616	5	Phase 3	Research only	intravenous →	65
Angiotensin-(1-7)	Heart and circulation	Medium	1,426	32	Phase 4	Research only	—	65
Copeptin	Heart and circulation	Medium	1,380	99	Phase 4	Research only	—	65
Galanin	Focus, mood and the brain	Medium	1,341	25	—	Research only	—	65
PACAP	Focus, mood and the brain	Medium	1,341	36	Phase 4	Research only	—	65
Neurokinin A	Immune defence and infection	Medium	694	27	Phase 4	Research only	—	65
Urocortin	Heart and circulation	Medium	594	6	Phase 2	Research only	—	65
Melanin-concentrating hormone	Weight loss and metabolism	Medium	570	4	—	Research only	—	65
INSL3	Sexual and reproductive health	Medium	486	7	—	Research only	—	65
Neurokinin B	Sexual and reproductive health	Medium	476	14	Phase 3	Research only	—	65
Des-acyl Ghrelin (Unacylated Ghrelin)	Weight loss and metabolism	Medium	324	28	Phase 3	Research only	—	65
Tuftsin	Immune defence and infection	Medium	232	3	—	Research only	—	65
Oxyntomodulin	Weight loss and metabolism	Medium	231	28	Phase 2	Research only	—	65
Uroguanylin	Weight loss and metabolism	Medium	206	4	—	Research only	—	65
Vessel dilator	Heart and circulation	Medium	118	1	—	Research only	—	65
Pal-GHK	Skin and hair	Medium	117	3	—	Research only	—	65
Somatrem	Growth hormone and body composition	Medium	94	11	—	Discontinued	injection →	65
Lixivaptan	Heart and circulation	Medium	93	11	Phase 3	Discontinued	oral →	65
Depreotide	Diagnostic and research tools	Medium	90	1	—	Discontinued	—	65
Demoxytocin	Sexual and reproductive health	Medium	80	5	—	Discontinued	buccal →	65
Ramoplanin	Immune defence and infection	Medium	64	1	—	Discontinued	oral →	65
Argireline	Skin and hair	Medium	60	3	Phase 3	Research only	topical →	65
Deslorelin	Sexual and reproductive health	Medium	55	27	Phase 3	Veterinary	—	65
Technetium Tc 99m Apcitide	Diagnostic and research tools	Medium	41	4	—	Discontinued	intravenous →	65
Emodepside	Diagnostic and research tools	Medium	39	23	Phase 3	Veterinary	oral →	65
Xenin	Weight loss and metabolism	Medium	38	2	Phase 1	Research only	intravenous →	65
Danuglipron	In development	Medium	37	5	Phase 2	Discontinued	—	65
Ipamorelin	Growth hormone and body composition	Medium	29	2	Phase 2	Research only	—	65
CJC-1295	Growth hormone and body composition	Medium	25	1	Phase 2	Research only	—	65
Selepressin	Heart and circulation	Medium	22	1	Phase 3	Discontinued	intravenous →	65
Nemifitide	Focus, mood and the brain	Medium	18	6	—	Discontinued	subcutaneous →	65
Pegbelfermin	In development	Medium	17	5	Phase 2	Discontinued	subcutaneous →	65
Technetium Tc 99m Etarfolatide	Diagnostic and research tools	Medium	17	2	Phase 2	Discontinued	intravenous →	65
Rotigaptide	Heart and circulation	Medium	15	2	Phase 2	Discontinued	intra-arterial (research study) →	65
Posatirelin	Focus, mood and the brain	Medium	8	2	—	Discontinued	intramuscular →	65
Detirelix	Sexual and reproductive health	Medium	5	1	—	Discontinued	subcutaneous →	65
Modimelanotide	Immune defence and infection	Medium	5	1	—	Discontinued	intravenous →	65
Porcine Insulin Zinc Suspension	Weight loss and metabolism	Medium	5	2	—	Veterinary	—	65
Kisspeptin-54	Sexual and reproductive health	Medium	1,231	29	Phase 3	In trials	—	60
Thymosin β4	Healing, injury and recovery	Medium	595	8	Phase 2	In trials	—	60
Carperitide	Heart and circulation	Medium	539	33	Phase 4	Approved abroad	—	60
Thymopentin	Immune defence and infection	Medium	459	54	Phase 3	Approved abroad	subcutaneous →	60
Cagrilintide	Weight loss and metabolism	Medium	403	75	Phase 3	In trials	subcutaneous →	60
Beinaglutide	Weight loss and metabolism	Medium	331	65	Phase 4	Approved abroad	—	60
Certepetide	Diagnostic and research tools	Medium	301	0	Phase 2	In trials	intravenous →	60
Felypressin	Heart and circulation	Medium	171	27	Phase 4	Approved abroad	local submucosal injection (dental) →	60
GHRP-2	Growth hormone and body composition	Medium	161	43	—	Approved abroad	intravenous →	60
HYNIC-TOC	Diagnostic and research tools	Medium	132	0	Phase 2	Approved abroad	intravenous →	60
Davunetide	Focus, mood and the brain	Medium	119	10	Phase 3	In trials	intranasal →	60
Larazotide	Healing, injury and recovery	Medium	72	6	Phase 3	In trials	oral →	60
FAP-2286	Diagnostic and research tools	Medium	61	0	Phase 2	In trials	intravenous →	60
Semax	Focus, mood and the brain	Medium	54	1	—	Approved abroad	—	60
Tesofensine	Diagnostic and research tools	Medium	48	11	Phase 2	In trials	oral →	60
Selank	Focus, mood and the brain	Medium	45	3	—	Approved abroad	—	60
ARA-290	Healing, injury and recovery	Medium	41	4	Phase 2	In trials	subcutaneous →	60
Edratide	Immune defence and infection	Medium	41	0	Phase 2	Approved abroad	subcutaneous →	60
3PRGD2	Diagnostic and research tools	Medium	40	0	—	In trials	intravenous →	60
Relamorelin	In development	Medium	40	10	Phase 3	In trials	subcutaneous →	60
Ubiquicidin 29-41	Diagnostic and research tools	Medium	39	0	—	In trials	intravenous →	60
Petrelintide	In development	Medium	32	7	Phase 3	In trials	subcutaneous →	60
Trivehexin	Diagnostic and research tools	Medium	31	0	—	In trials	intravenous →	60
Glepaglutide	In development	Medium	26	8	Phase 3	In trials	subcutaneous →	60
AlF-NOTA-octreotide	Diagnostic and research tools	Medium	25	0	Phase 3	In trials	intravenous →	60
NeoB	Diagnostic and research tools	Medium	22	0	Phase 2	In trials	intravenous →	60
Taltirelin	Focus, mood and the brain	Medium	22	0	Phase 4	Approved abroad	oral →	60
FPPRGD2	Diagnostic and research tools	Medium	18	0	Phase 2	In trials	intravenous →	60
Amycretin	In development	Medium	15	4	Phase 1	In trials	subcutaneous or oral →	60
Maridebart cafraglutide	In development	Medium	15	2	Phase 3	In trials	subcutaneous →	60
Balixafortide	Diagnostic and research tools	Medium	13	0	Phase 3	In trials	—	60
Satoreotide Tetraxetan	Diagnostic and research tools	Medium	13	0	Phase 2	In trials	intravenous →	60
Fluciclatide	Diagnostic and research tools	Medium	12	0	Phase 2	In trials	intravenous →	60
Tozuleristide	Diagnostic and research tools	Medium	11	0	Phase 3	In trials	intravenous →	60
DOTA-EB-TATE	Diagnostic and research tools	Medium	9	0	Phase 2	In trials	intravenous →	60
NODAGA-exendin-4	Diagnostic and research tools	Medium	9	0	Phase 2	In trials	intravenous →	60
Pemvidutide	In development	Medium	9	2	Phase 3	In trials	subcutaneous →	60
CP04	Diagnostic and research tools	Medium	8	0	Phase 3	In trials	intravenous →	60
DOTA-MGS5	Diagnostic and research tools	Medium	8	0	Phase 2	In trials	intravenous →	60
Zelenectide Pevedotin	Diagnostic and research tools	Medium	8	0	Phase 2	In trials	intravenous →	60
Pegmolesatide	Heart and circulation	Medium	6	0	Phase 4	Approved abroad	subcutaneous →	60
Eneboparatide	In development	Medium	5	0	Phase 3	In trials	subcutaneous →	60
SARTATE	Diagnostic and research tools	Medium	5	0	Phase 2	In trials	—	60
DOTAMTATE	Diagnostic and research tools	Medium	4	0	Phase 2	In trials	intravenous →	60
Enicepatide	In development	Medium	2	1	Phase 3	In trials	subcutaneous →	60
Dapiglutide	Weight loss and metabolism	Medium	1	0	Phase 2	In trials	—	60
Eftansomatropin alfa	In development	Medium	1	1	—	Approved abroad	—	60
SAR-bisPSMA	Diagnostic and research tools	Medium	1	0	Phase 3	In trials	—	60
UBT251	In development	Medium	0	0	Phase 3	In trials	subcutaneous →	60
Gonadorelin	Sexual and reproductive health	Medium	24,018	2,458	Phase 4	Discontinued	intravenous or subcutaneous pump →	55
GLP-1	Weight loss and metabolism	Medium	19,633	2,316	Phase 4	Research only	—	55
Collagen Peptides	Skin and hair	Medium	16,927	1,173	Phase 4	Supplement	—	55
Ghrelin	Growth hormone and body composition	Medium	11,055	1,685	Phase 4	Research only	—	55
CGRP	Heart and circulation	Medium	9,803	561	Phase 4	Research only	—	55
Substance P	Immune defence and infection	Medium	9,219	505	Phase 4	Research only	—	55
Beta-Endorphin	Focus, mood and the brain	Medium	7,648	477	Phase 4	Research only	—	55
GIP	Weight loss and metabolism	Medium	6,652	768	Phase 4	Research only	—	55
Neuropeptide Y	Focus, mood and the brain	Medium	6,034	149	Phase 4	Research only	—	55
Enkephalin	Focus, mood and the brain	Medium	4,742	89	Phase 3	Research only	—	55
Adrenomedullin	Heart and circulation	Medium	2,757	84	Phase 2	Research only	—	55
Klotho Peptide	Longevity and cell health	Medium	2,669	67	Phase 4	Research only	—	55
Lutropin alfa	Sexual and reproductive health	Medium	2,526	294	Phase 4	Discontinued	subcutaneous →	55
Pentagastrin	Weight loss and metabolism	Medium	2,164	167	Phase 4	Discontinued	—	55
Apelin	Heart and circulation	Medium	1,675	42	Phase 4	Research only	—	55
Melittin	Immune defence and infection	Medium	1,486	13	—	Research only	—	55
Carnosine	Longevity and cell health	Medium	1,386	158	Phase 4	Supplement	—	55
GLP-2	Weight loss and metabolism	Medium	1,210	185	Phase 4	Research only	—	55
Histatin	Healing, injury and recovery	Medium	671	26	—	Research only	—	55
Mecasermin rinfabate	Growth hormone and body composition	Medium	623	21	Phase 4	Discontinued	—	55
Capreomycin	Immune defence and infection	Medium	482	0	Phase 4	Discontinued	—	55
GHRP-6	Growth hormone and body composition	Medium	323	25	—	Research only	—	55
NAD+	Longevity and cell health	Medium	314	16	Phase 4	Research only	—	55
Sermorelin	Growth hormone and body composition	Medium	291	38	Phase 4	Discontinued	—	55
Melanocyte-stimulating hormone beta	Weight loss and metabolism	Medium	254	0	Phase 4	Research only	—	55
Dermcidin	Immune defence and infection	Medium	232	2	—	Research only	—	55
Hexarelin	Growth hormone and body composition	Medium	193	27	—	Research only	—	55
Pancreastatin	Weight loss and metabolism	Medium	178	0	Phase 4	Research only	—	55
Bioactive Food Peptides	Diagnostic and research tools	Medium	176	8	Phase 4	Supplement	—	55
Neuromedin U	Weight loss and metabolism	Medium	176	0	—	Research only	—	55
DSIP	Focus, mood and the brain	Medium	141	6	—	Research only	—	55
MK-677	Growth hormone and body composition	Medium	105	19	Phase 3	Research only	oral →	55
Melanotan II	Sexual and reproductive health	Medium	104	1	Phase 2	Research only	—	55
GHK-Cu	Healing, injury and recovery	Medium	67	3	Phase 4	Research only	—	55
Tifuvirtide	Immune defence and infection	Medium	64	1	—	Discontinued	subcutaneous →	55
Zoptarelin Doxorubicin	Diagnostic and research tools	Medium	58	0	Phase 3	Discontinued	—	55
Cotadutide	In development	Medium	51	14	Phase 2	Discontinued	subcutaneous →	55
ACE-031	Diagnostic and research tools	Medium	29	2	Phase 2	Discontinued	subcutaneous →	55
Seglitide	In development	Medium	25	0	—	Discontinued	intravenous →	55
Palmitoyl Pentapeptide-4	Skin and hair	Medium	22	2	—	Research only	topical →	55
Balenine	Diagnostic and research tools	Medium	14	0	—	Research only	oral →	55
Insulin tregopil	Weight loss and metabolism	Low	4,298	212	Phase 3	In trials	oral →	50
Murabutide	Immune defence and infection	Low	46	3	—	Approved abroad	not stated in the abstract →	50
Pentixather	Diagnostic and research tools	Medium	35	0	Phase 2	In trials	intravenous →	50
Galacto-RGD	Diagnostic and research tools	Medium	32	0	—	In trials	intravenous →	50
Noopept	Focus, mood and the brain	Medium	31	0	—	Approved abroad	—	50
Cenderitide	Heart and circulation	Low	29	2	Phase 2	In trials	—	50
SiTATE	Diagnostic and research tools	Medium	27	0	—	In trials	intravenous →	50
Rusalatide	Healing, injury and recovery	Low	23	1	Phase 2	Approved abroad	topical (to the ulcer) →	50
Prostatilen	Longevity and cell health	Low	18	2	—	Approved abroad	intramuscular →	50
Retinalamin	Longevity and cell health	Low	16	3	—	Approved abroad	intramuscular →	50
LSALT peptide	In development	Low	4	1	Phase 3	In trials	intravenous infusion →	50
Taldefgrobep alfa	In development	Medium	4	0	Phase 3	In trials	—	50
Efmedaglutide alfa	In development	Low	3	2	—	In trials	subcutaneous →	50
PSMA I&S	Diagnostic and research tools	Medium	3	0	Phase 2	In trials	intravenous →	50
VMT-α-NET	Diagnostic and research tools	Medium	3	0	Phase 2	In trials	intravenous →	50
Tiplimotide	Immune defence and infection	Medium	2	0	—	Approved abroad	subcutaneous →	50
Osteocalcin	Healing, injury and recovery	Low	12,534	1,211	Phase 4	Research only	—	45
Gastrin	Weight loss and metabolism	Low	9,845	459	Phase 4	Research only	intravenous →	45
Dynorphin	Focus, mood and the brain	Low	9,350	190	Phase 4	Research only	—	45
Irisin	Weight loss and metabolism	Low	1,637	103	Phase 4	Research only	—	45
Motilin	Weight loss and metabolism	Low	1,150	180	Phase 4	Research only	—	45
Ceruletide	Weight loss and metabolism	Low	1,051	50	—	Discontinued	—	45
Muramyl Dipeptide	Immune defence and infection	Low	704	9	Phase 2	Research only	—	45
Nociceptin	Focus, mood and the brain	Low	694	15	Phase 4	Research only	intravesical →	45
Agouti-Related Peptide (AgRP)	Weight loss and metabolism	Low	687	15	—	Research only	—	45
Urotensin II	Heart and circulation	Low	579	10	Phase 2	Research only	—	45
Beta-lipotropin	Growth hormone and body composition	Low	552	16	Phase 4	Research only	—	45
Nesfatin-1	Weight loss and metabolism	Low	407	11	—	Research only	—	45
Obestatin	Weight loss and metabolism	Low	356	13	Phase 4	Research only	—	45
Lactoferricin	Immune defence and infection	Medium	242	0	—	Research only	—	45
Asprosin	Weight loss and metabolism	Low	236	16	Phase 4	Research only	—	45
Endomorphin-1	Focus, mood and the brain	Low	210	9	—	Research only	—	45
Cortistatin	Growth hormone and body composition	Low	194	5	Phase 4	Research only	—	45
Neuropeptide S	Focus, mood and the brain	Low	193	1	Phase 4	Research only	—	45
Goralatide	Heart and circulation	Low	178	10	Phase 2	Research only	—	45
Catestatin	Heart and circulation	Low	174	1	Phase 4	Research only	—	45
Glicentin	Weight loss and metabolism	Low	161	10	—	Research only	—	45
Secretoneurin (SN)	Heart and circulation	Low	153	1	—	Research only	—	45
PHM-27	Weight loss and metabolism	Low	130	2	Phase 4	Research only	—	45
Urocortin 2	Heart and circulation	Low	129	2	—	Research only	intravenous →	45
Spexin	Weight loss and metabolism	Low	122	6	—	Research only	not applicable →	45
Lunasin	Diagnostic and research tools	Low	85	1	Phase 2	Research only	—	45
Tripeptide-29	Skin and hair	Low	79	8	—	Research only	—	45
Katacalcin	Diagnostic and research tools	Medium	68	0	Phase 4	Research only	—	45
Cyclo(His-Pro)	Diagnostic and research tools	Low	56	1	Phase 2	Research only	intravenous →	45
Preptin	Weight loss and metabolism	Low	48	1	Phase 2	Research only	—	45
Enterostatin	Weight loss and metabolism	Low	47	2	—	Research only	oral →	45
D-4F	Heart and circulation	Low	42	1	—	Research only	oral →	45
KR-12	Healing, injury and recovery	Medium	42	0	—	Research only	—	45
FK-13	Healing, injury and recovery	Medium	33	0	—	Research only	—	45
Colostrinin	Focus, mood and the brain	Low	30	2	—	Supplement	oral (sublingual) →	45
NERP-2 (Neuroendocrine Regulatory Peptide-2)	Weight loss and metabolism	Low	27	2	—	Research only	—	45
WE-14	Weight loss and metabolism	Low	21	2	—	Research only	—	45
AOD-9604	Weight loss and metabolism	Medium	19	0	—	Research only	—	45
SHLP2	Longevity and cell health	Medium	16	0	—	Research only	—	45
Tetrapeptide-21	Skin and hair	Low	8	2	—	Research only	—	45
Decapeptide-12	Skin and hair	Low	6	1	—	Research only	—	45
Tetrapeptide-30	Skin and hair	Low	6	2	—	Research only	—	45
Palmitoyl Tetrapeptide-7	Skin and hair	Low	5	1	Phase 4	Research only	—	45
Acetyl Dipeptide-1 Cetyl Ester	Skin and hair	Low	4	2	—	Research only	—	45
Ebiratide	Focus, mood and the brain	Low	4	1	—	Discontinued	intravenous (research) →	45
Livoletide	Weight loss and metabolism	Low	4	2	Phase 3	Discontinued	subcutaneous →	45
Palmitoyl Dipeptide-7	Skin and hair	Low	3	1	—	Research only	—	45
Nonapeptide-1	Skin and hair	Low	2	1	—	Research only	—	45
Aclerastide	Healing, injury and recovery	Low	1	1	Phase 3	Discontinued	topical →	45
Avorelin	Sexual and reproductive health	Low	1	1	—	Discontinued	subcutaneous →	45
Feline Interferon Omega	Immune defence and infection	Low	1	8	—	Veterinary	—	45
Hexapeptide-9	Skin and hair	Low	1	1	—	Research only	—	45
Oligopeptide-68	Skin and hair	Low	1	1	—	Research only	—	45
HRS-9531	In development	Medium	0	0	Phase 3	In trials	subcutaneous →	45
Lecirelin	Sexual and reproductive health	Low	0	6	—	Veterinary	—	45
Olatorepatide	In development	Medium	0	0	Phase 3	In trials	—	45
Cortexin	Focus, mood and the brain	Low	3,669	46	—	Approved abroad	intramuscular or intravenous →	40
Thymalin	Longevity and cell health	Low	200	2	—	Approved abroad	—	40
Thymogen	Longevity and cell health	Low	94	7	—	Approved abroad	—	40
Ruxotemitide	Diagnostic and research tools	Low	39	0	Phase 2	In trials	intratumoral →	40
Thymodepressin	Immune defence and infection	Low	6	0	—	Approved abroad	intramuscular →	40
Dolcanatide	Healing, injury and recovery	Low	4	0	Phase 2	Approved abroad	oral →	40
HM15136	In development	Low	3	2	Phase 2	In trials	—	40
KN056	In development	Low	1	1	Phase 1	In trials	subcutaneous →	40
Zelpultide alfa	In development	Low	0	0	Phase 3	In trials	intratracheal →	40
Glutathione	Longevity and cell health	Low	61,221	1,879	Phase 4	Research only	—	35
Vasostatin (Chromogranin A)	Heart and circulation	Low	32,893	4,614	Phase 4	Research only	—	35
P21	Focus, mood and the brain	Low	25,382	52	Phase 2	Research only	—	35
MGF	Diagnostic and research tools	Low	9,581	316	Phase 4	Research only	—	35
Elabela	Heart and circulation	Low	6,423	430	Phase 4	Research only	—	35
Alpha-MSH	Immune defence and infection	Low	4,689	67	Phase 3	Research only	—	35
Amylin	Weight loss and metabolism	Low	3,602	213	Phase 4	Research only	—	35
LL-37	Healing, injury and recovery	Low	2,821	56	Phase 3	Research only	—	35
Cathelicidin	Immune defence and infection	Low	2,786	55	Phase 4	Research only	—	35
Orexin-A	Focus, mood and the brain	Low	2,184	47	Phase 4	Research only	—	35
Orexin-B	Focus, mood and the brain	Low	2,005	44	Phase 4	Research only	—	35
HD5	Immune defence and infection	Low	1,975	67	Phase 1	Research only	—	35
Follistatin-344	Diagnostic and research tools	Low	1,733	68	Phase 1	Preclinical	—	35
hBD-2	Immune defence and infection	Low	1,424	29	Phase 2	Research only	—	35
CNP	Heart and circulation	Low	996	29	Phase 4	Research only	—	35
PAMP (Proadrenomedullin N-terminal 20 Peptide)	Heart and circulation	Low	819	7	—	Research only	—	35
hBD-1	Immune defence and infection	Low	787	10	Phase 4	Research only	—	35
Equine Chorionic Gonadotropin	Sexual and reproductive health	Low	716	58	—	Veterinary	—	35
hBD-3	Immune defence and infection	Low	705	5	—	Research only	—	35
Thymulin	Immune defence and infection	Low	615	10	—	Research only	—	35
HNP-1	Immune defence and infection	Low	485	6	Phase 3	Research only	—	35
Humanin	Longevity and cell health	Low	335	6	—	Research only	—	35
GDF11	Longevity and cell health	Low	322	4	—	Research only	—	35
Lypressin	Weight loss and metabolism	Low	303	20	Phase 4	Discontinued	—	35
Magainin	Immune defence and infection	Low	292	1	—	Research only	—	35
Montirelin	Focus, mood and the brain	Low	268	20	Phase 4	Discontinued	—	35
Cecropin	Immune defence and infection	Low	259	3	—	Research only	—	35
Adropin	Weight loss and metabolism	Low	256	13	—	Research only	—	35
Vilon	Longevity and cell health	Low	229	3	—	Research only	—	35
Neuromedin B	Weight loss and metabolism	Low	203	2	—	Research only	—	35
Prokineticin 1 (EG-VEGF)	Sexual and reproductive health	Low	180	2	—	Research only	—	35
Thiostrepton	Immune defence and infection	Low	170	0	Phase 2	Research only	sourced dose →	35
HD6	Immune defence and infection	Low	167	7	Phase 1	Research only	—	35
Prolyl-Hydroxyproline	Diagnostic and research tools	Low	166	8	—	Research only	—	35
MOTS-c	Longevity and cell health	Low	152	4	Phase 2	Research only	—	35
Urocortin 3	Weight loss and metabolism	Low	151	2	—	Research only	—	35
Kyotorphin	Focus, mood and the brain	Low	133	3	Phase 4	Research only	—	35
Prolactin-releasing peptide	Weight loss and metabolism	Low	107	3	Phase 4	Research only	—	35
Indolicidin	Immune defence and infection	Low	96	2	—	Research only	—	35
RFRP-3 (GnIH)	Sexual and reproductive health	Low	86	3	—	Research only	—	35
Salusin-beta	Heart and circulation	Low	81	1	Phase 4	Research only	—	35
Deltorphin	Focus, mood and the brain	Low	74	1	—	Research only	—	35
Porcine FSH	Sexual and reproductive health	Low	73	28	—	Veterinary	—	35
Teprotide	Heart and circulation	Low	68	0	—	Research only	intravenous →	35
Virginiamycin	Immune defence and infection	Low	68	21	—	Veterinary	—	35
Phoenixin	Sexual and reproductive health	Low	67	0	—	Research only	—	35
Dermorphin	Diagnostic and research tools	Low	61	1	—	Research only	—	35
Neuropeptide AF (NPAF)	Weight loss and metabolism	Low	54	2	—	Research only	—	35
IGF-1 LR3	Diagnostic and research tools	Low	41	1	—	Research only	—	35
Hemopressin (Hp)	Weight loss and metabolism	Low	32	1	—	Research only	—	35
Epithalamin	Longevity and cell health	Low	30	5	—	Research only	—	35
Vesugen	Longevity and cell health	Low	27	0	—	Research only	—	35
GHRP-1	Growth hormone and body composition	Low	24	3	Phase 2	Research only	—	35
Pinealon	Longevity and cell health	Low	23	0	—	Research only	oral (capsule) →	35
EM66	Weight loss and metabolism	Low	18	0	—	Research only	—	35
PE-22-28	Focus, mood and the brain	Low	18	1	—	Research only	—	35
Thymoctonan	Immune defence and infection	Low	18	0	—	Discontinued	intramuscular →	35
Chromofungin	Heart and circulation	Low	15	0	—	Research only	—	35
Ovagen	Longevity and cell health	Low	15	2	—	Research only	—	35
GAWK (Chromogranin B 420-493)	Weight loss and metabolism	Low	11	0	—	Research only	—	35
Alexamorelin	Growth hormone and body composition	Low	8	0	—	Research only	intravenous →	35
Nosiheptide	Immune defence and infection	Low	8	2	—	Research only	—	35
GnRF Analogue–Diphtheria Toxoid Conjugate	Sexual and reproductive health	Low	7	20	—	Veterinary	—	35
Tabimorelin	In development	Low	7	4	—	Discontinued	oral →	35
Hexapeptide-11	Skin and hair	Low	5	0	—	Research only	—	35
PEG-MGF	Diagnostic and research tools	Low	5	1	Phase 2	Research only	—	35
Peforelin	Sexual and reproductive health	Low	4	3	—	Veterinary	—	35
Manserin	Focus, mood and the brain	Low	3	0	—	Research only	—	35
Palmitoyl Tripeptide-38	Skin and hair	Low	3	0	—	Research only	—	35
Palmitoyl Tripeptide-5	Skin and hair	Low	3	0	Phase 4	Research only	—	35
Tripeptide-10 Citrulline	Skin and hair	Low	3	1	—	Research only	—	35
Acetyl Octapeptide-3	Skin and hair	Low	1	0	—	Research only	—	35
Acetyl Tetrapeptide-2	Skin and hair	Low	1	1	—	Research only	—	35
Acetyl Tetrapeptide-3	Skin and hair	Low	0	0	—	Research only	—	35
Azagly-nafarelin	Sexual and reproductive health	Low	0	0	—	Veterinary	—	35
Gonadorelin (6-D-Phe)	Sexual and reproductive health	Low	0	0	—	Veterinary	—	35
Veldoreotide	In development	Low	13	0	Phase 1	Approved abroad	—	30
Prostamax	Longevity and cell health	Low	8	0	—	Approved abroad	—	30
Nendratareotide Uzatansine	Diagnostic and research tools	Low	5	0	—	Approved abroad	—	30
Efocipegtrutide	In development	Low	4	0	Phase 2	In trials	—	30
Trevogrumab	In development	Low	4	0	Phase 2	In trials	—	30
Ozarelix	Sexual and reproductive health	Low	3	0	Phase 2	Approved abroad	—	30
AZD6234	In development	Low	2	0	Phase 3	In trials	—	30
Leconotide	Focus, mood and the brain	Low	1	0	—	Approved abroad	—	30
Obinepitide	In development	Low	1	0	—	In trials	—	30
Sonefpeglutide	In development	Low	1	0	Phase 2	In trials	—	30
Testagen	Longevity and cell health	Low	1	0	Phase 2	Approved abroad	—	30
Utreglutide	In development	Low	1	0	—	In trials	—	30
Sometribove	Growth hormone and body composition	Low	0	13	—	Veterinary	—	30
Galanin-like Peptide (GALP)	Weight loss and metabolism	Low	481	0	—	Research only	—	25
Apamin	Focus, mood and the brain	Low	480	0	—	Research only	—	25
Guanylin	Weight loss and metabolism	Low	248	0	—	Research only	—	25
Prokineticin 2	Focus, mood and the brain	Low	234	0	—	Research only	—	25
Adrenomedullin 2	Heart and circulation	Low	170	0	Phase 2	Research only	—	25
Neuropeptide FF (NPFF)	Focus, mood and the brain	Low	169	0	—	Research only	—	25
Relaxin-3	Focus, mood and the brain	Low	152	0	—	Research only	—	25
INSL5	Weight loss and metabolism	Low	103	0	—	Research only	—	25
Augurin (ECRG4)	Immune defence and infection	Low	89	0	—	Research only	—	25
CART peptide	Weight loss and metabolism	Low	66	0	Phase 2	Research only	—	25
Salusin-alpha	Heart and circulation	Low	63	0	Phase 4	Research only	—	25
QRFP (26RFa)	Weight loss and metabolism	Low	61	0	—	Research only	—	25
Chonluten	Longevity and cell health	Low	58	0	—	Research only	—	25
BPC-157	Healing, injury and recovery	Low	54	0	Phase 2	Research only	—	25
Epithalon	Longevity and cell health	Low	51	0	Early Phase 1	Research only	—	25
Neuromedin N (NN)	Focus, mood and the brain	Low	47	0	—	Research only	—	25
Osteogenic growth peptide	Healing, injury and recovery	Low	47	0	Phase 2	Research only	—	25
KPV	Healing, injury and recovery	Low	45	0	—	Research only	—	25
Corticotropin-like intermediate peptide (CLIP)	Diagnostic and research tools	Low	40	0	—	Research only	—	25
Urotensin II-related peptide	Heart and circulation	Low	38	0	—	Research only	—	25
Cartalax	Longevity and cell health	Low	35	0	—	Research only	—	25
Hexapeptide-10	Skin and hair	Low	32	0	—	Research only	—	25
Teixobactin	Immune defence and infection	Low	32	0	—	Preclinical	—	25
Neuropeptide B (NPB)	Weight loss and metabolism	Low	29	0	—	Research only	—	25
Neuropeptide W (NPW)	Weight loss and metabolism	Low	29	0	—	Research only	—	25
Nocistatin (NST)	Focus, mood and the brain	Low	27	0	—	Research only	—	25
Cardiogen	Longevity and cell health	Low	26	0	—	Research only	—	25
Cortagen	Longevity and cell health	Low	26	0	—	Research only	—	25
Dipeptide-2	Skin and hair	Low	25	0	—	Research only	—	25
TB-500	Healing, injury and recovery	Low	25	0	Phase 2	Research only	—	25
Glypromate	Focus, mood and the brain	Low	24	0	—	Research only	—	25
TLQP-21	Weight loss and metabolism	Low	24	0	—	Research only	—	25
Plectasin	Immune defence and infection	Low	20	0	—	Preclinical	—	25
Livagen	Longevity and cell health	Low	19	0	—	Research only	—	25
Neuromedin S	Focus, mood and the brain	Low	18	0	—	Research only	—	25
PNC-27	Diagnostic and research tools	Low	18	0	—	Preclinical	—	25
Follistatin-315	Diagnostic and research tools	Low	15	0	—	Preclinical	—	25
SHLP6	Longevity and cell health	Low	15	0	—	Research only	—	25
Adamax	Focus, mood and the brain	Low	14	0	—	Research only	—	25
IGF-1 DES(1-3)	Diagnostic and research tools	Low	14	0	—	Research only	—	25
Cyclic Glycine-Proline	Diagnostic and research tools	Low	13	0	—	Research only	—	25
Leuphasyl	Skin and hair	Low	11	0	—	Research only	—	25
B7-33	Heart and circulation	Low	10	0	—	Preclinical	—	25
Dihexa	Focus, mood and the brain	Low	9	0	—	Research only	—	25
FOXO4-DRI	Longevity and cell health	Low	9	0	—	Preclinical	—	25
PEPITEM	Immune defence and infection	Low	9	0	—	Preclinical	—	25
TCAP-1 (Teneurin C-terminal Associated Peptide-1)	Focus, mood and the brain	Low	9	0	—	Research only	—	25
Adipotide	Diagnostic and research tools	Low	8	0	—	Preclinical	—	25
Davalintide	Weight loss and metabolism	Low	8	0	Phase 2	Discontinued	—	25
Pancragen	Weight loss and metabolism	Low	8	0	—	Research only	—	25
Bronchogen	Longevity and cell health	Low	7	0	—	Research only	—	25
Neuropeptide EI (NEI)	Focus, mood and the brain	Low	7	0	—	Research only	—	25
GHRP-4	Growth hormone and body composition	Low	6	0	—	Research only	—	25
GHRP-5	Growth hormone and body composition	Low	6	0	—	Research only	—	25
Serpinin	Heart and circulation	Low	6	0	—	Research only	—	25
Pentapeptide-3	Skin and hair	Low	4	0	—	Research only	—	25
Tetrapeptide-1	Skin and hair	Low	4	0	—	Research only	—	25
5-Amino-1MQ	Weight loss and metabolism	Low	3	0	—	Research only	—	25
Azetirelin	Focus, mood and the brain	Low	3	0	—	Discontinued	—	25
CJC-1293	Growth hormone and body composition	Low	3	0	—	Research only	—	25
Acetyl Hexapeptide-1	Skin and hair	Low	2	0	—	Research only	—	25
Palmitoyl Tripeptide-8	Skin and hair	Low	2	0	—	Research only	—	25
Syn-Ake	Skin and hair	Low	2	0	—	Research only	—	25
Acetyl Tetrapeptide-11	Skin and hair	Low	1	0	—	Research only	—	25
Acetyl Tetrapeptide-5	Skin and hair	Low	1	0	—	Research only	—	25
Acetyl Tetrapeptide-9	Skin and hair	Low	1	0	—	Research only	—	25
AHK-Cu	Skin and hair	Low	1	0	Early Phase 1	Research only	—	25
FGL Peptide	Focus, mood and the brain	Low	1	0	—	Research only	—	25
Hexapeptide-33	Skin and hair	Low	1	0	—	Research only	—	25
Palmitoyl Hexapeptide-12	Skin and hair	Low	1	0	—	Research only	—	25
Palmitoyl Tetrapeptide-20	Skin and hair	Low	1	0	—	Research only	—	25
Cerluten	Longevity and cell health	Low	0	0	—	Approved abroad	—	25
Endoluten	Longevity and cell health	Low	0	0	—	Approved abroad	—	25
GMA106	In development	Low	0	0	Phase 1	In trials	—	25
HM15275	In development	Low	0	0	Phase 2	In trials	—	25
PB-718	In development	Low	0	0	Phase 2	In trials	—	25
Ventfort	Longevity and cell health	Low	0	0	—	Approved abroad	—	25
Visoluten	Longevity and cell health	Low	0	0	—	Approved abroad	—	25
Acetyl Decapeptide-3	Skin and hair	Low	0	0	—	Research only	—	20
Acetyl Dipeptide-3 Aminohexanoate	Skin and hair	Low	0	0	—	Research only	—	20
Acetyl Heptapeptide-4	Skin and hair	Low	0	0	—	Research only	—	20
Acetyl Hexapeptide-30	Skin and hair	Low	0	0	—	Research only	—	20
Acetyl Hexapeptide-37	Skin and hair	Low	0	0	—	Research only	—	20
Acetyl Hexapeptide-38	Skin and hair	Low	0	0	—	Research only	—	20
Acetyl Hexapeptide-49	Skin and hair	Low	0	0	—	Research only	—	20
Acetyl Hexapeptide-51 Amide	Skin and hair	Low	0	0	—	Research only	—	20
Acetyl Pentapeptide-1	Skin and hair	Low	0	0	—	Research only	—	20
Acetyl SH-Heptapeptide-1	Skin and hair	Low	0	0	—	Research only	—	20
Acetyl Tetrapeptide-15	Skin and hair	Low	0	0	—	Research only	—	20
Acetyl Tetrapeptide-22	Skin and hair	Low	0	0	—	Research only	—	20
Acetyl Tripeptide-1	Skin and hair	Low	0	0	—	Research only	—	20
Biotinoyl Tripeptide-1	Skin and hair	Low	0	0	—	Research only	—	20
BRN2 (POU3F2) Research Peptide	Focus, mood and the brain	Low	0	0	—	Research only	—	20
Caprooyl Tetrapeptide-3	Skin and hair	Low	0	0	—	Research only	—	20
Colulintide	In development	Low	0	0	—	Discontinued	—	20
Elsiglutide	In development	Low	0	0	Phase 2	Discontinued	—	20
Hexanoyl Dipeptide-3 Norleucine Acetate	Skin and hair	Low	0	0	—	Research only	—	20
Mod GRF 1-29	Growth hormone and body composition	Low	0	0	—	Research only	—	20
Myristoyl Hexapeptide-16	Skin and hair	Low	0	0	—	Research only	—	20
Myristoyl Pentapeptide-17	Skin and hair	Low	0	0	—	Research only	—	20
Myristoyl Tetrapeptide-12	Skin and hair	Low	0	0	—	Research only	—	20
NA-Selank Amidate	Focus, mood and the brain	Low	0	0	—	Research only	—	20
NPAS3 Research Peptide	Focus, mood and the brain	Low	0	0	—	Research only	—	20
Octapeptide-2	Skin and hair	Low	0	0	—	Research only	—	20
Palmitoyl Dipeptide-10	Skin and hair	Low	0	0	Phase 4	Research only	—	20
Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine	Skin and hair	Low	0	0	—	Research only	—	20
Palmitoyl Dipeptide-5 Diaminohydroxybutyrate	Skin and hair	Low	0	0	—	Research only	—	20
Palmitoyl Hexapeptide-14	Skin and hair	Low	0	0	—	Research only	—	20
Palmitoyl Tetrapeptide-10	Skin and hair	Low	0	0	—	Research only	—	20
Palmitoyl Tripeptide-28	Skin and hair	Low	0	0	—	Research only	—	20
Pegbovigrastim	Immune defence and infection	Low	0	0	—	Veterinary	—	20
Pentapeptide-31	Skin and hair	Low	0	0	—	Research only	—	20
Tetrapeptide-26	Skin and hair	Low	0	0	—	Research only	—	20
Trifluoroacetyl Tripeptide-2	Skin and hair	Low	0	0	—	Research only	—	20
Tripeptide-32	Skin and hair	Low	0	0	—	Research only	—	20

No peptide matches those filters.

How the evidence score works

Evidence score (0-100), a transparent ranking aid, not a verdict. grade: high=60, medium=40, low=20, ungraded=0. Human trial: an on-site read-and-cited randomized or clinical trial = +15, else any PubMed human-indexed record = +5, else 0. RCT literature: PubMed lists >=1 randomized controlled trial = +10. Regulatory: FDA-approved = +15, in trials / approved-abroad / in development = +5, else 0. Every component is stored on each record so the number can be re-derived; volume and grade are shown together so neither misleads.

“Human studies” and “RCTs” are PubMed record counts for the peptide (read 2026-11-07 from the counts behind the Evidence Explorer); a count is how much research exists and of what kind, never proof a peptide works. “Grade” is our editorial reading of the evidence — see how we grade evidence. The “Dose” column links to the entry for each peptide that carries a dose from a regulator’s label or a published human study — where the amount is shown with its source; the amount is never reprinted here without that source, and many research peptides have no human dose, shown as —. Of 660 peptides, 607 have at least one human-indexed PubMed record, 324 cite a human trial on their page, 124 are FDA-approved, and 271 carry a sourced dose.